J D Baumgartner
Overview
Explore the profile of J D Baumgartner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
877
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baumgartner J, Cometta A, Fumeaux T
Rev Med Suisse
. 2007 Dec;
3(133):2579-80.
PMID: 18078186
No abstract available.
2.
Bochud P, Calandra T, Moreillon P, Baumgartner J, Yersin B
Eur J Clin Microbiol Infect Dis
. 2001 Apr;
20(2):136-7.
PMID: 11305469
No abstract available.
3.
Delarive P, Baumgartner J, Glauser M, Cometta A
Schweiz Med Wochenschr
. 2001 Jan;
130(48):1837-44.
PMID: 11132527
The benefits of oral prophylaxis for neutropenia have remained controversial up to now. We evaluated retrospectively the effect of antibiotic prophylaxis with ciprofloxacin and penicillin on the prevention of bacterial...
4.
Baumgartner J, Calandra T
Drugs
. 1999 Apr;
57(2):127-32.
PMID: 10188756
In recent years, the concept has emerged that the host's inflammatory response contributes substantially to the development of septic shock and organ failure. Experimental observations prompted large scale randomised clinical...
5.
de Werra I, Jaccard C, Corradin S, Chiolero R, Yersin B, Gallati H, et al.
Crit Care Med
. 1997 Apr;
25(4):607-13.
PMID: 9142024
Objectives: To determine and compare the respective concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, soluble TNF receptors, nitrite/nitrate (NO2-/NO3-), and procalcitonin in the plasma of patients with septic shock,...
6.
Zanetti G, Baumgartner J, Glauser M
Schweiz Med Wochenschr
. 1997 Mar;
127(12):489-99.
PMID: 9106949
Focal infectious processes may produce a systemic syndrome whose description has been recently standardized by the definitions of sepsis, severe sepsis and septic shock. This classification should only be used...
7.
Bailat S, Heumann D, Le Roy D, Baumgartner J, Rietschel E, Glauser M, et al.
Infect Immun
. 1997 Feb;
65(2):811-4.
PMID: 9009348
We have previously described cross-reactive antilipopolysaccharide (anti-LPS), or anti-endotoxin, monoclonal antibodies (MAbs) which provide cross-protection in several systems of endotoxin bioactivity. The protective effects of the murine cross-reactive MAb WN1...
8.
Cometta A, Baumgartner J
Schweiz Med Wochenschr Suppl
. 1996 Jan;
76:28S-33S.
PMID: 8677416
Until recently, aminoglycoside antibiotics were the cornerstone for the treatment of severe infections. The rationale for using combination therapy containing beta-lactams and aminoglycosides was not only to broaden the antimicrobial...
9.
Cometta A, Baumgartner J, Glauser M
Clin Exp Immunol
. 1994 Jul;
97 Suppl 1:69-72.
PMID: 8033438
Infections remain the leading cause of death among patients admitted to intensive care units (ICU). Infections due to Gram-negative bacteria are both frequent and difficult to treat. The poor outcome...
10.
Cometta A, Baumgartner J, Lew D, Zimmerli W, Pittet D, Chopart P, et al.
Antimicrob Agents Chemother
. 1994 Jun;
38(6):1309-13.
PMID: 8092830
Nosocomial pneumonia and sepsis, as well as severe diffuse peritonitis, must be treated early in order to prevent complications such as septic shock and organ dysfunctions. With the availability of...